Evidence map›Paper›PMID 40528666›Full record

ArticleACR open rheumatology2025

Trends in Systemic Lupus Erythematous Mortality in the United States, 1999-2022.

Sagar Patel, Joseph Bettag, Nikita Baral, Abubakar Tauseef, Ali Bin Abdul Jabbar

Abstract read
In one paragraph

Article in ACR open rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sagar PatelCreighton University School of Medicine, Phoenix, Arizona.ORCID https://orcid.org/0009-0004-0189-0946
Joseph BettagCreighton University School of Medicine, Omaha, Nebraska.
Nikita BaralCreighton University School of Medicine, Omaha, Nebraska.
Abubakar TauseefCreighton University School of Medicine, Omaha, Nebraska.
Ali Bin Abdul JabbarCreighton University School of Medicine, Omaha, Nebraska.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSystemic lupus erythematosus (SLE) is a chronic autoimmune disease with variable mortality rates among different demographic groups. Despite treatment advancements, disparities in SLE outcomes continue to exist.

methodsThis study used the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research database data from 1999 to 2022 to examine SLE-related mortality trends. Age-adjusted mortality rates (AAMRs) were calculated, and Joinpoint regression was employed to evaluate annual percentage changes (APCs) over time for mortality stratified by gender, race, census regions, age groups, and states.

resultsA total of 52,430 SLE-related deaths occurred over the study period. The AAMR decreased from 1 per 100,000 in 1999 to 0.78 per 100,000 in 2022. The AAMR of SLE-related deaths decreased by 21% from 1 in 1999 to 0.79 in 2019 (average APC -1.23, 95% confidence interval -1.48 to -0.96). It increased by 21.52% from 0.79 in 2019 to 0.96 in 2021. From 1999 to 2019, men decreased by 33.33% compared to 21.02% in women, whereas women saw a more considerable increase from 2019 to 2021. Non-Hispanic Asians or Pacific Islander patients saw the most decrease (-43.37%), followed by Hispanic patients (-40.60%), non-Hispanic African American patients (-25.83%), and non-Hispanic White patients (-21.43%). Hispanic patients saw the most significant increase from 2019 to 2021, whereas non-Hispanic African American patients had the highest AAMR among all racial and ethnic subgroups from 1999 to 2022. The South had the highest AAMR throughout the study period among census regions.

conclusionPersistent disparities have been observed in SLE-related mortality rates from 1999 to 2022, with female sex, non-Hispanic African American race, and southern region being disproportionately impacted by worse mortality outcomes.

Identifiers

PMID40528666
PMCPMC12174472

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.